About this item
Product details
Rezna (Resmetirom) 100 mg is the higher-dose, once-daily oral tablet from the first FDA-approved medication for metabolic dysfunction-associated steatohepatitis (MASH). Manufactured by Nabiqasim, it is specifically indicated for adults with moderate to advanced liver fibrosis (stages F2-F3). This 100 mg strength offers a dosing option for optimized individual treatment response under specialist supervision. First FDA-Approved MASH Therapy: A landmark treatment for a previously untreatable progressive liver disease. Clinically Validated Efficacy: Demonstrated significant rates of MASH resolution and liver fat reduction in pivotal trials. Fibrosis Impact: Treatment can lead to fibrosis improvement, slowing disease progression toward cirrhosis. Mechanism of Action: A selective thyroid hormone receptor-beta (THR-β) agonist that targets the liver to restore metabolic health and reduce lipotoxicity. Composition Each film coated tablet contains: Resmetirom: 100 mg Directions for Use As directed by the doctor.
- Medicines
- 14 Film Coated Tablets
- 1 variant
- Protected Dastak checkout
Know before you buy
Specifications
- Department
- Health
- Subcategory
- Medicines
- Brand
- Nabiqasim
- SKU
- 08964003525187
- Variant
- 14 Film Coated Tablets
- Tags
- Medicine, Resmetirom
- Condition
- New
Customer feedback
Ratings & reviews
For help with a purchase, open your orders or contact Dastak support.
